Iridian Asset Management LLC CT decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,005,952 shares of the biopharmaceutical company’s stock after selling 603,041 shares during the period. Iridian Asset Management LLC CT owned approximately 7.05% of Halozyme Therapeutics worth $173,803,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HALO. Teacher Retirement System of Texas purchased a new stake in Halozyme Therapeutics during the second quarter valued at about $129,000. Arrowstreet Capital Limited Partnership purchased a new stake in Halozyme Therapeutics during the second quarter valued at about $131,000. Prudential Financial Inc. raised its position in Halozyme Therapeutics by 8.7% during the second quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 940 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Halozyme Therapeutics during the second quarter valued at about $171,000. Finally, Amalgamated Bank raised its position in Halozyme Therapeutics by 5.3% during the second quarter. Amalgamated Bank now owns 14,067 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 705 shares in the last quarter. Institutional investors and hedge funds own 83.28% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.truebluetribune.com/2017/11/17/iridian-asset-management-llc-ct-lowers-holdings-in-halozyme-therapeutics-inc-halo.html.
A number of equities research analysts have weighed in on the company. Canaccord Genuity raised their price target on Halozyme Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. BMO Capital Markets raised their price target on Halozyme Therapeutics from $15.00 to $18.00 and gave the company a “market perform” rating in a research report on Wednesday, November 8th. Piper Jaffray Companies raised their price target on Halozyme Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Monday, October 16th. Zacks Investment Research downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, October 6th. Finally, Deutsche Bank AG raised their price target on Halozyme Therapeutics to $20.00 and gave the company a “buy” rating in a research report on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $17.75.
Shares of Halozyme Therapeutics, Inc. (NASDAQ HALO) traded up $0.24 during trading hours on Friday, hitting $18.49. The stock had a trading volume of 828,600 shares, compared to its average volume of 1,418,700. Halozyme Therapeutics, Inc. has a 52-week low of $9.68 and a 52-week high of $19.37. The company has a current ratio of 3.46, a quick ratio of 3.37 and a debt-to-equity ratio of 2.01.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.06 by ($0.04). The company had revenue of $63.73 million for the quarter, compared to the consensus estimate of $58.95 million. Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. The firm’s quarterly revenue was up 100.1% compared to the same quarter last year. During the same period last year, the business posted ($0.23) earnings per share. analysts anticipate that Halozyme Therapeutics, Inc. will post 0.15 EPS for the current year.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.